Cargando…

Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer

SIMPLE SUMMARY: IMAGiC model is the model consisting of four-gene and PD-L1 expression levels to predict immunotherapy response. The IMAGiC model’s predictive performance was validated in patients with several advanced tumor types in this study. The PFS and OS demonstrated significant differences be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jin-Chul, Heo, You-Jeong, Kang, So-Young, Lee, Jeeyun, Kim, Kyoung-Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151730/ https://www.ncbi.nlm.nih.gov/pubmed/34065963 http://dx.doi.org/10.3390/cancers13102316

Ejemplares similares

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
por: Kim, Jinchul, et al.
Publicado: (2020)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue
por: Heo, You Jeong, et al.
Publicado: (2019)

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma
por: Kang, So Young, et al.
Publicado: (2022)

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
por: Lee, Hansang, et al.
Publicado: (2016)

PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression
por: Kim, Binnari, et al.
Publicado: (2020)

Computational measurement of tumor immune microenvironment in gastric adenocarcinomas
por: Chang, Young Hwan, et al.
Publicado: (2018)

Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer
por: Jeong, Young-IL, et al.
Publicado: (2019)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

DNA-protein biomarkers for immunotherapy in the era of precision oncology
por: Kim, Binnari, et al.
Publicado: (2021)

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
por: Cho, Junhun, et al.
Publicado: (2018)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hyojin, et al.
Publicado: (2022)

Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody
por: Kim, Nalee, et al.
Publicado: (2021)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy
por: Pallocca, Matteo, et al.
Publicado: (2019)

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
por: Garmezy, Benjamin, et al.
Publicado: (2022)

Digital image analysis in pathologist‐selected regions of interest predicts survival more accurately than whole‐slide analysis: a direct comparison study in 153 gastric carcinomas
por: Heo, You Jeong, et al.
Publicado: (2020)

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
por: Kim, Ryul, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
por: Choi, Sangjoon, et al.
Publicado: (2022)

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma
por: Lee, Jeeyun, et al.
Publicado: (2012)

Dysregulated miRNA in a cancer-prone environment: A study of gastric non-neoplastic mucosa
por: Kim, Binnari, et al.
Publicado: (2020)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
por: Lapuente-Santana, Óscar, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors
por: Kim, Yongjin, et al.
Publicado: (2023)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bah2tid7i1bbjfjniudpnmv3rp